[Skip to Content]
[Skip to Content Landing]
Views 732
Citations 0
Comment & Response
March 6, 2019

Autism Risk and Serotonin Reuptake Inhibitors

Author Affiliations
  • 1Child Study Center, Yale University School of Medicine, New Haven, Connecticut
  • 2Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut
JAMA Psychiatry. 2019;76(5):547-548. doi:10.1001/jamapsychiatry.2019.0073

To the Editor In their article published in the December 2018 issue of JAMA Psychiatry entitled “Association of Autism Spectrum Disorder With Prenatal Exposure to Medication Affecting Neurotransmitter Systems,”1 Janecka et al made several statements and conclusions that do not appear warranted. The problem stems from an inappropriate grouping of agents thought to affect the serotonin transporter. Specifically, the decongestant pseudoephedrine was included in the group along with known selective and nonselective reuptake inhibitors. The inclusion of pseudoephedrine is clearly in error as pseudoephedrine has been shown to have very little or no affinity for the transporter.2,3